Cowen & Co. upgraded Genmark Diagnostics (NASDAQ:GNMK) from Market Perform to Outperform in a report released today.
- Updated: September 16, 2016
Cowen & Co. has upgraded Genmark Diagnostics(NASDAQ:GNMK) from Market Perform to Outperform in a statement released on 9/16/2016.
On 10/14/2015, Cowen reported on Genmark Diagnostics(NASDAQ:GNMK) lowered the target price from $15.00 to $11.00 that suggested an upside of 0.34%.
Yesterday Genmark Diagnostics (NASDAQ:GNMK) traded 16.44% higher at $10.40. The company’s 50-day moving average is $9.10 and its 200-day average is $7.51. The last stock close is up 36.70% relative to the 200-day moving average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. 1,192,393 shares of GNMK traded, up from ann avg. trading volume of 286,652.
Genmark Diagnostics has a 52 week low of $4.20 and a 52 week high of $11.31 . Genmark Diagnostics’s market cap is currently $0.0.
General Company Details For Genmark Diagnostics (NASDAQ:GNMK)
GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, and Thrombophilia Risk Test and Respiratory Viral Panel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.